Brittany Cote

Articles

Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian Cancer

January 11th 2021

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.

Investigators Take Stock of New Landscape for Metastatic HER2-Positive Breast Cancer

November 26th 2020

Breast cancer specialists discuss noteworthy data on efficacy and safety about fam-trastuzumab deruxtecan-nxki, neratinib, and tucatinib.

I-SPY2: A Revolutionary Effort to Advance Personalized Care in Breast Cancer

November 3rd 2020

Claudine J. Isaacs, MD, discusses significant advances that have been made across all different breast cancer subtypes in recent years, as well as ongoing research efforts.

Tucatinib Triplet Takes Up Residence in Third-Line Metastatic HER2+ Breast Cancer

November 2nd 2020

Elisavet Paplomata, MD, discusses the lack of standard third-line regimens for patients with metastatic HER2-positive breast cancer, especially for those with brain metastases.

Research Efforts Strive to Overcome Osimertinib Resistance in EGFR+ Lung Cancer

November 2nd 2020

Helena A. Yu, MD, discusses novel non–small cell lung cancer combinations and biomarkers that are under investigation in order to overcome osimertinib resistance

More Clinical Trials Needed to Overcome PARP Inhibitor Resistance in Ovarian Cancer

November 2nd 2020

Gottfried E. Konecny, MD, discusses potential strategies to overcome PARP resistance, future combinations with PARP inhibitors, and other unmet needs in ovarian cancer.

Shaping a New Future With Novel Therapeutics in Gynecologic Cancers

October 31st 2020

Ritu Salani, MD, MBA, discusses updates to PARP inhibition and FRα-targeting agents in ovarian cancer, the role of bevacizumab across all lines of ovarian cancer therapy, and immunotherapy highlights in cervical and endometrial cancer.

Chemoimmunotherapy Combos “Game-Changing” in Frontline Metastatic NSCLC

October 30th 2020

Nicholas Rohs, MD, discusses the progress made with chemoimmunotherapy combinations in frontline non–small cell lung cancer, future research directions, and emerging approaches that seek to propel progress in this disease.

Schiffer Spotlights Potential for TKI Discontinuation in Select Patients With CML

October 28th 2020

Charles Schiffer, MD, discusses integration of TKIs, such as imatinib, into the chronic myeloid leukemia treatment paradigm.

Enzalutamide Plus ADT Improves rPFS in Metastatic Hormone-Sensitive Prostate Cancer, Regardless of Baseline PSA Levels

October 27th 2020

The addition of enzalutamide to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer improved radiographic progression-free survival, regardless of baseline prostate-specific antigen levels.

MRD Negativity Remains Key Goal in Frontline Myeloma Treatment

October 27th 2020

Andrew Kin, MD, discusses the shift in goals for frontline treatment in multiple myeloma.

Pralsetinib and Selpercatinib Expand the RET+ NSCLC Paradigm

October 27th 2020

Justin F. Gainor, MD, discusses the recent FDA approvals of pralsetinib and selpercatinib, which led to expanded treatment options for patients with non–small cell lung cancer who harbor RET rearrangements.

Borghaei Stresses Importance of Immunotherapy Biomarkers in Frontline Advanced NSCLC Treatment

October 26th 2020

Hossein Borghaei, DO, MS, further discusses the benefit of immunotherapy combinations, the potential of tiragolumab, and the need for better biomarkers to guide treatment in NSCLC.

Fourth-Line Ripretinib Elicits Significant Responses in Advanced GIST

October 22nd 2020

César Serrano-García, MD, PhD, highlights ripretinib and the meaningful benefit it provides as a fourth- and later-line therapy in patients with advanced gastrointestinal stromal tumor who harbor KIT or PDGFRA mutations.

Hari Reviews Recent Data in Relapsed/Refectory Multiple Myeloma

October 22nd 2020

Parameswaran Hari, MD, MRCP, discusses key data that has read out in relapsed/refractory multiple myeloma, exciting agents generating excitement, and the role of minimal residual disease.

O’Regan Weighs Escalation, De-Escalation Approaches in Early-Stage HER2+ Breast Cancer

October 21st 2020

In an interview with OncLive Ruth O’Regan, MD, discusses the challenges faced with personalizing treatment in early-stage HER2-positive breast cancer

CAR T-Cell Therapy Enters a New Era in Lymphomas, But More Lessons to Learn

October 20th 2020

Brian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have shifted lymphoma treatment into a new era.

Ripretinib Continues to Showcase Clinically Meaningful Benefit, Safety in Advanced GIST

October 19th 2020

Ripretinib continues to show clinically meaningful benefit with an acceptable safety profile when used as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumor.

Tolaney Touches on HER2+ -Low Breast Cancer Testing, Possibilities, and Challenges

October 16th 2020

Sara M. Tolaney, MD, MPH, discusses the challenges in treating patients with heterogenous HER2 expression and what treatments could potentially improve outcomes for this subgroup.

Nazha Navigates Emerging Approaches for Polycythemia Vera Post Hydroxyurea

October 16th 2020

Aziz Nazha, MD, discusses risk stratification in polycythemia vera, options that have emerged for patients, approaches to consider following hydroxyurea, and the need for agents that will reverse fibrosis in the bone marrow.